Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Short Report
7 April 2025

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

Authors: Isha Mol https://orcid.org/0009-0009-6366-9178 [email protected], Yannan Hu, Thomas W LeBlanc https://orcid.org/0000-0002-0546-7895, Joseph C Cappelleri, Haitao Chu https://orcid.org/0000-0003-0932-598X, Guido Nador, Didem Aydin, Isabel Perez Cruz, and Patrick HlavacekAuthor Info & Affiliations
Volume 14, Number 5
https://doi.org/10.57264/cer-2024-0236
PDFFormats

Abstract

Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma, there is a lack of consensus on the optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT04035226) study reported significant improvements in progression-free survival (PFS) and overall survival (OS) with elranatamab versus physician’s choice of treatment. Materials & methods: We conducted an updated MAIC based on more recent data (28.4 months for MagnetisMM-3). Following reweighting of MagnetisMM-3 individual patient data to match the LocoMMotion population, the effective sample size was 64 for PFS and 63 for OS in the base-case analysis. Results: Consistent with the original MAIC, significantly improved PFS (hazard ratio [HR] [95% confidence interval (CI)]: 0.32 [0.21, 0.50], p < 0.01) and OS (HR [95% CI]: 0.50 [0.33, 0.78], p < 0.01) were observed with elranatamab versus physician’s choice of treatment. The robustness of the results was demonstrated in sensitivity analyses in which missing baseline characteristics data for elranatamab were imputed. Conclusion: Overall, the findings of this study align with and add confidence to the conclusions of the previous MAIC that elranatamab is associated with significantly improved outcomes versus standard treatment, supporting the value to elranatamab for the treatment of patients with triple-class exposed/refractory multiple myeloma.

Plain language summary

What is this article about?

Multiple myeloma (MM) is a blood cancer that becomes harder to treat after multiple therapies stop working. Patients with triple-class exposed/refractory (TCE/R) MM have already received treatments from the three main drug classes used for MM, but their cancer has either not responded or has come back. These patients have very few treatment options and tend to have poor outcomes. Elranatamab is a type of treatment called a bispecific antibody, which helps the immune system recognize and attack MM cells in patients with TCE/R MM. This study indirectly compared elranatamab to a physician’s choice of treatment (PCT) based on data from a prospective study LocoMMotion. Since there are no clinical trials that directly compare elranatamab to PCT, a methodology known as matching-adjusted indirect comparison was conducted. This method helps account for differences between the patient groups in the two studies, making the comparison as fair and accurate as possible.

What were the results?

The results showed that elranatamab had significantly longer survival outcomes compared with PCT, based on longer-term follow-up data from the elranatamab clinical trial.

What do the results mean?

These findings suggest that elranatamab may be a more effective treatment option than current standard therapies for patients with TCE/R MM.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 20(1), 1–7 (2020).
PubMed
Google Scholar
2.
Munshi NC, Anderson LD Jr, Shah N et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384(8), 705–716 (2021).
PubMed
Google Scholar
3.
Berdeja JG, Madduri D, Usmani SZ et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase Ib/II open-label study. Lancet 398(10297), 314–324 (2021).
PubMed
Google Scholar
4.
Chari A, Minnema MC, Berdeja JG et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387(24), 2232–2244 (2022).
PubMed
Google Scholar
5.
Lesokhin AM, Tomasson MH, Arnulf B et al. Elranatamab in relapsed or refractory multiple myeloma: phase II MagnetisMM-3 trial results. Nat. Med. 29(9), 2259–2267 (2023).
PubMed
Google Scholar
• Presents the study results of MagnetisMM-3 based on the 15-month data cut off.
6.
US Food and Drug Administration. Highlights of prescribing information. ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use. Initial US approval: 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf
Google Scholar
7.
Mateos MV, Weisel K, De Stefano V et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis). Leukemia 38(12), 2554–2560 (2024).
PubMed
Google Scholar
•• Presents the study results of the LocoMMotion study based on the 2-year follow-up data.
8.
Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016). Available from: https://research-information.bris.ac.uk/ws/portalfiles/portal/94868463/Population_adjustment_TSD_FINAL.pdf
Google Scholar
9.
Mol I, Hu Y, LeBlanc TW et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Curr. Med. Res. Opin. 40(2), 199–207 (2024).
PubMed
Google Scholar
•• Presents the results of the previous matching-adjusted indirect comparison conducted between elranatamab versus physician’s choice of treatment based on the LocoMMotion study.
10.
Tomasson MH, Iida S, Niesvizky R et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere 8(7), e136 (2024).
PubMed
Google Scholar
•• Presents the longer follow-up study results of the MagnetisMM-3 trial.
11.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200–211 (2018).
PubMed
Google Scholar
12.
Malard F, Bobin A, Labopin M et al. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 14(1), 219 (2024).
PubMed
Google Scholar
|